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ABSTRACT
Autologous hematopoietic stem cell transplantation (HSCT) is being explored in the treatment of severe
multiple sclerosis (MS), and is based on the concept of “resetting” the immune system. The use of allogeneic
HSCT may offer additional advantages, such as the replacement of the autoreactive immune compartment by
healthy allogeneic cells and development of a graft-versus-autoimmunity (GVA) effect. However, in clinical
practice, the genetic susceptibility to MS of allogeneic stem cell donors is generally unknown, and GVA may
therefore be an important mechanism of action. Experimental autoimmune encephalomyelitis (EAE)-suscep-
tible and -resistant mouse strains were used to determine the roles of genetic susceptibility, level of donor-
chimerism, and alloreactivity in the therapeutic potential of syngeneic versus allogeneic bone marrow trans-
plant (BMT) for EAE. After transplantation and EAE induction, animals were evaluated for clinical EAE and
ex vivo myelin oligodendrocyte glycoprotein-specific proliferation. Early after BMT, both syngeneic and
allogeneic chimeras were protected from EAE development. On the longer term, allogeneic but not syngeneic
BMT conferred protection, but this required high-level donor-chimerism from EAE-resistant donors. Importantly,
when EAE-susceptible donors were used, robust protection from EAE was obtained when active alloreactivity,
induced by donor lymphocyte infusions, was provided. Our findings indicate the requirement of a sufficient level of
donor-chimerism from a nonsusceptible donor in the therapeutic effect of allogeneic BMT. Importantly, the data
indicate that, independently of genetic susceptibility, active alloreactivity is associated with a GVA effect, thereby
providing new evidence to support the potential role of allogeneic BMT in the treatment of MS.
© 2007 American Society for Blood and Marrow Transplantation
KEY WORDS
Bone marrow transplantation ● Graft-versus-autoimmunity ● Experimental autoimmune
encephalomyelitis ● Multiple sclerosis ● Donor lymphocyte infusion
l
[
o
d
c
m
t
r
sNTRODUCTION
Multiple Sclerosis (MS) is the most frequent im-
une-mediated demyelinating disease of the central
ervous system (CNS), affecting mainly young adults,
nd leads to physical and cognitive impairment [1].
urrently, the standard treatment options for MS are
he immune modulators -interferon and glatiramer
cetate, or immunosuppressants such as mitoxantrone
2]. Both types of drugs have been shown to reduce
isease activity in relapsing-remitting MS, but have a cimited effect on the progressive course of the disease
3-5]. Nevertheless, these therapeutic approaches are
nly partially effective and fail to achieve satisfactory
isease control in a number of patients, probably be-
ause of incomplete suppression and persistence of
yelin-reactive T cells.
The assumptions that ablation of the immune sys-
em would include destruction of the autoreactive
epertoire, and that reconstitution with hematopoietic
tem cells would lead to “resetting” of the immune
ompartment and to restoration of unresponsiveness
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B. Van Wijmeersch et al.628o self-antigens, have led investigators to study the
ffects of autologous hematopoietic stem cell trans-
lantation (HSCT) in MS [6-12]. In their retrospec-
ive multicenter study, Fassas et al. [6] reviewed 85
rogressive MS patients, treated with various proto-
ols of autologous HSCT and followed for a mean
ime of 16 months. A 3-year progression-free survival
f 74% and a disease activity-free survival of 55%
ere documented. However, a signiﬁcant mortality
isk of 10% was described, mostly resulting from toxic
nd infectious complications.
Several case reports exist that illustrate the poten-
ial therapeutic effect of allogeneic HSCT in the
reatment of autoimmune disorders such as systemic
upus erythematosus and MS [13-17]. The replace-
ent of the recipient’s autoreactive immune com-
artment by allogeneic immune cells from a healthy
ndividual, which is not genetically predisposed for
utoimmunity, may not only eliminate the genetic
usceptibility, but, in addition to high-grade immuno-
uppression, the alloreactive donor lymphocytes may
xert a graft-versus-autoimmunity (GVA) effect: sim-
lar to the graft-versus-leukemia (GVL) effect of allo-
eneic HSCT for hematologic malignancies, alloreac-
ive T cells may, during engraftment, eliminate the
utoreactive T cells from the host [18], preventing
utoimmune manifestations from reoccurring.
Experimental autoimmune encephalomyelitis (EAE)
s the most widely used experimental animal model for
S, and can be induced in susceptible rodent strains
y either in vivo sensitization with myelin antigens or
y adoptive transfer of ex vivo primed CD4 T cells
19,20]. Previous rodent studies have demonstrated
hat syngeneic and allogeneic BMT, as a therapeutic
pproach (ie, BMT after the onset of EAE), can confer
n almost complete protection from further disease
elapses [21-26]. Using syngeneic bone marrow trans-
lantation (BMT) models, Karussis et al. [21] pro-
ided some support for a mechanism of clonal deletion
r anergy, and Herrmann et al. [27] obtained evidence
f a regulatory mechanism, a shift in T cell epitope
ecognition and a reduction of autoantibodies. How-
ver, the mechanisms of action underlying the pos-
ible reeducation of the immune system following
yngeneic BMT are still incompletely understood.
reviously reported experimental studies on alloge-
eic BMT have made use of EAE-resistant donor
trains and have demonstrated that this approach can
ffectuate a change in the genetic EAE susceptibility
f recipient mice [24]. In clinical practice, however,
he susceptibility status of BM donors is generally
nknown, and the therapeutic effect of this approach
ay therefore not be sufﬁcient unless the BM graft
ounts a GVA response.
Here, we performed syngeneic and allogeneic
MT between EAE-susceptible and EAE-resistant
ouse strains to investigate the roles of the genetic busceptibility, the level of donor-type chimerism, and
ost-BMT alloreactivity in the prevention of EAE.
e provide evidence that, early after transplantation,
oth syngeneic and allogeneic BMT confer protection
rom EAE, probably because of aspeciﬁc immunosup-
ression after the conditioning. However, later after
MT, a longer term and stronger protection from
AE is achieved only by allogeneic BMT, either by
roviding a sufﬁcient level of donor-chimerism from
n EAE-resistant donor or on the basis of donor
eukocyte infusion (DLI)-induced alloreactivity in an
AE-susceptible background.
ATERIALS AND METHODS
nimals
Animals were purchased from Janvier (France).
en- to 12-week-old C57BL/6 (H-2Kb, Thy 1.2) and
6SJLF1 (H-2Ks/b, Thy 1.2) female mice were used as
ecipients and 6- to 12-week-old C57BL/6 and Balb/c
H-2Kd, Thy 1.2) female mice as donors.
one Marrow Transplantation
Recipient C57BL/6 or B6SJLF1 mice were con-
itioned with lethal (9.5 Gy) total body irradiation
TBI) using a linear accelerator 18 MEV photons
General Electric, Baden, Switzerland) and a dose rate
f 3.9 Gy/min with focus to midbody distance of 100
m. One day afterward, C57BL/6 recipients were re-
onstituted with a mixture of 5-10  106 T cell-
epleted host-type C57BL/6 and 10-15  106 non-T
ell-depleted donor-type Balb/c BM cells, a protocol
reviously shown to allow induction of mixed chimer-
sm without graft versus host disease (GVHD) [28],
nd B6SJLF1 recipients were reconstituted with 5 
06 T cell-depleted donor-type C57BL/6 BM cells
dministered intravenously in 250 L RPMI 1640. T
ell depletion was performed using cytotoxic comple-
ent-ﬁxing anti-Thy1.2 antibody and low-toxic rab-
it complement (Serotec, Oxford, UK), as described
reviously [29].
onor Leukocyte Infusion (DLI)
At the speciﬁed time points, the mice were infused
ith donor-type splenocytes. Donor-type spleen tis-
ue was aseptically removed and placed in RPMI 1640
n ice. A single-cell suspension was prepared by push-
ng splenic tissue through a cell strainer. The cells
ere washed twice, counted, and resuspended at 100
r 200  106 cells per milliliter. Chimeric mice were
njected in a tail vein with 250 L of this cell suspen-
ion.
etermination of Chimerism
At regular time intervals after BMT, peripheral
lood lymphocytes (PBLs) and/or spleen cells were stud-
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GVA Effect in EAE 629ed by ﬂow cytometry using the FACStar Plus (Becton
ickinson Biosciences, Erembodegem, Belgium). Ve-
ous blood was obtained from the animals by cutting the
ail and red blood cells were lysed using ammonium
hloride (NH4Cl). Splenocytes were brought into single
ell suspension. The cells were labeled with ﬂuores-
ein isothiocyanate (FITC)-, phycoerythrin (PE)-,
eridinin chlorophyll protein (PerCP)- or PE-Cy5-
onjugated antibodies directed against CD3, CD45R/
220, H-2Ks, and H-2Kd (Becton Dickinson Bio-
ciences and eBioscience). Analysis of naive host- and
onor-type mice was included in every ﬂow cytomet-
ic study to ensure speciﬁcity of the anti-MHC I
onoclonal antibodies.
ixed Lymphocyte Reaction (MLR)
Responder cells (nylon wool-enriched chimeric or
ontrol splenocytes) and stimulator cells (host-type
plenocytes) were cultured for 5 days in RPMI 1640
upplemented with 10% fetal bovine serum (FBS),
ntibiotics, and 5  105 M 2-mercaptoethanol at a
oncentration of 5 106 cells per milliliter and a ratio
f 1:1 in a ﬁnal volume of 200 L per well in ﬂat-
ottomed 96-well microculture plates. Prior to cul-
ure, stimulator cells were treated with mitomycin C
Kyowa Hakko Kogyo, Tokyo, Japan), as described
reviously [18]. DNA synthesis was assayed by adding
Ci (0.037 MBq) (methyl-3H) thymidine (Radio
hemical Centre, Amersham, Buckinghamshire, UK)
er well during the last 18 hours of culture. Thereaf-
er, the cells were harvested on glass ﬁlter paper, and
he counts per minute were determined in a liquid
cintillation counter. Results are expressed as stimula-
ion index: SI  mean cpm of stimulated cells /mean
pm of nonstimulated cells.
nduction and Scoring of EAE
Acute EAE was induced by injecting 50 L of an
mulsion consisting of equal amounts of 500 g/mL
yelin oligodendrocyte glycoprotein peptide 35-55
MOG35-55) (Sigma-Aldrich, Bornem, Belgium, and
aul Proost, Rega Institute, Leuven, Belgium) in PBS
nd 4 mg/mL heat-killed Mycobacterium tuberculosis
strain H37Ra) in CFA (both reagents from Becton
ickinson Bioscience). The injection was performed
n each hind footpad on day 0. On day 0 and day 2, 200
g of Bordetella pertussis toxin (Sigma-Aldrich) in 200
L PBS was intravenously administered in the tail
ein. Each day and throughout the experiments, the
nimals were evaluated by the same observer. The
isease and mortality were scored on a scale of 0-6:
 normal; 0.5 ﬂoppy tail; 1 tail paralysis and mild
mpaired righting reﬂex; 2  mild hind limb weakness
nd impaired righting reﬂex; 3  moderate to severe
ind limb paresis and/or forelimb weakness; and 4 
ind leg paralysis and/or moderate to severe forelimb aeakness; 5  quadriplegia or moribund; 6  death.
nimals that died from EAE were given a score of 6
uring the further part of the experiment. Mean EAE
core was calculated as the average of the individual
ean EAE scores of diseased animals obtained
hroughout the relapse (non-diseased animals were
ot taken into account).
plenocyte Stimulation Assays
Single-cell suspensions were prepared from spleen
erived from naive mice or experimental mice that
ad been induced with MOG35-55 in CFA 10-13 days
efore. The ex vivo response of the splenocytes was
ssayed in quadruplicate, in 96-well ﬂat-bottom mi-
rotiter plates. A quantity of 2  105 splenocytes,
uspended in 200 L RPMI supplemented with 10%
etal calf serum (FCS) was added to each well and
timulated with 5 g/mL MOG35-55 (Sigma-Aldrich).
t 48 h after seeding, 1 Ci (0.037 MBq) (methyl-3H)
hymidine (Radio Chemical Centre) was added to
ach well, and the plates were incubated for an addi-
ional 18 h. Thereafter, the cells were harvested on
lass ﬁlter paper, and the counts per minute were
etermined in a liquid scintillation counter. Results
re again expressed as SI.
tatistics
The Fisher’s exact test and the Mann Whitney
-test were used to estimate the level of statistical
igniﬁcance of difference between groups of data (P 
05 was considered as evidence for statistical signiﬁ-
ance).
ESULTS
rotective Effect of Allogeneic BMT from an
AE-Resistant Donor Requires High-Grade
onor-Type Chimerism
First, the role of genetic susceptibility and degree
f donor chimerism were investigated in EAE-suscep-
ible C57BL/6 mice using EAE-resistant Balb/c donor
ice. To investigate possible intrinsic BMT proce-
ure-related effects, allogeneic BMT was performed
n comparison with syngeneic BMT.
Following TBI, EAE-susceptible C57BL/6-mice
H-2Kb) were transplanted with bone marrow from
yngeneic C57BL/6 mice (synBMT) or allogeneic
AE-resistant Balb/c (H-2Kd) donor-type mice
alloBMT). Selected groups of alloBMT mice were
iven DLI (50 106 donor-type splenocytes IV) at 21
ays after alloBMT (alloBMT/DLI), to establish high-
rade donor chimerism. Subsequently, MOG35-55-
AE was induced on day 28 or 42 after transplanta-
ion. On day 12 after EAE induction (d 40 or d 54),
he proliferative response of chimeric splenocytes
gainst MOG35-55 was tested ex vivo.
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B. Van Wijmeersch et al.630AlloBMT/DLI chimeras developed high-level do-
or chimerism on day 50 (77%  12.1% for T cells
nd 83%  3.4% for B cells, n  28), whereas al-
oBMT animals showed low-level donor chimerism
5%  1.5% for T cells and 13%  3.6% for B cells,
igure 1. Evolution of mean % donor T and B cell chimerism, mea
ssays against MOG35-55 in the Balb/c¡C57BL/6 transplantation
lloBMT/DLI, as determined by ﬂow cytometric analysis of periphe
f EAE on day 28 or day 42 after alloBMT, alloBMT/DLI, synBM
ndex of splenocyte stimulation assays against MOG35-55 after ind
ynBMT, compared to host- and donor-type EAE control animals. 56) (Figure 1a). In both groups similar CD4/CD8
atios were found within the host- and donor-type T
ell compartment (alloBMT/DLI: 1.22  0.36 versus
.37  0.16 and alloBMT: 1.37  0.1 versus 1.21 
.08 for host- versus donor-type T cells, respectively;
disease score, and mean stimulation index of splenocyte stimulation
. a, Mean % donor T and B cell chimerism after alloBMT and
od samples. b, Mean EAE score of diseased animals after induction
compared to host-type EAE control animals. c, Mean stimuation
of EAE on day 28 or day 42 after alloBMT, alloBMT/DLI, andn EAE
model
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GVA Effect in EAE 631S, Mann-Whitney U ). EAE induction on day 28
esulted in an EAE incidence of 38% (n  8) in
ynBMT mice versus 18% (n  17) in alloBMT and
% (n  5) in alloBMT/DLI chimeras (p  .05 for
ynBMT, P  .05 for alloBMT/DLI, P  .001 for
lloBMT, compared to EAE incidence in host-type
ontrol mice (82%, n  11), Fisher’s exact). However,
hen EAE was induced on day 42, EAE incidences
ere 90% (n  19) in synBMT and 68% (n  34) in
lloBMT chimeras, whereas 100% (n  9) resistance
o EAE in the alloBMT/DLI group was maintained
Table 1) (P  .001 for alloBMT/DLI compared to
ost-type control mice (94%, n  17), NS for al-
oBMT and synBMT, Fisher’s exact). The mean dis-
ase scores and clinical course of EAE in transplanted
nimals were not signiﬁcantly different from those in
ontrol EAE host-type mice (Table 1 and Figure 1b)
d 28-induction: mean EAE score  SEM of 1.1 
.4, 1.3  0.5, 1.3  0.3 for synBMT, alloBMT, and
ontrol host-type EAE mice, respectively, NS, Mann-
hitney U ) (d 42-induction: mean EAE score 
EM of 1.3  0.2, 1.1  0.2, 1.1  0.2 for synBMT,
lloBMT, and control host-type EAE mice, respec-
ively, NS, Mann-Whitney U ). Both after d 28 and
42 EAE induction, MOG35-55 speciﬁc proliferation
ssays showed a complete loss of proliferative response
n alloBMT/DLI chimeras, whereas similarly high
roliferative responses were seen after EAE induction
n synBMT, alloBMT, and control donor- and host-
ype EAE mice (Figure 1c) (d 28-induction: mean
I SEM of 4.6 0.6, 4.3 0.8, 5.1 0.9, 3.3 0.5
or synBMT, alloBMT, control host, and donor-type
AE, respectively, NS, Mann-Whitney U; mean SI 
EM 1.1  0.3 for alloBMT/DLI, P  .05 compared
o control host-type EAE, Mann-Whitney U ) (d 42-
nduction: mean SI  SEM of 4.6  1.3, 3.5  0.5,
.8  1.1, 3.3  0.5 for synBMT, alloBMT, and
ontrol host and donor-type EAE, respectively, NS,
ann-Whitney U; mean SI  SEM 1.3  0.2 for
lloBMT/DLI, P  .05 compared to control host-
ype EAE, Mann-Whitney U ).
These data indicate that syngeneic BMT and low-
rade allogeneic chimerism provide protection from
linical EAE development early in the posttransplan-
ation period only, and ex vivo MOG35-55-reactive
esponses are unaffected. In contrast, high-grade allo-
eneic chimerism from an EAE-resistant donor con-
ers longer term clinical protection from EAE and loss
f ex vivo MOG35-55-reactive response.
igh-Grade Donor-Type Chimerism after
llogeneic BMT from an EAE-Susceptible
onor Does Not Confer Protection from EAE
To conﬁrm the role of genetic susceptibility in the
rotective effect of allogeneic BMT, high-grade allo-
eneic radiation chimeras were generated using EAE-
usceptible C57BL/6 mice as donors, in B6SJLF1 Ta Ba Ba C5 C5 C5 B6 C5 Co Co Co NS EA *P **P
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B. Van Wijmeersch et al.632ice, known to be EAE-susceptible as well [30].
igh-grade chimerism was intended because this pro-
ided the strongest clinical protection in the case of
AE-resistant donors (as shown above).
Following TBI, host-type B6SJLF1 mice (H-
Kb/s) were transplanted with either syngeneic
6SJLF1 (synBMT/F1) or allogeneic C57BL/6 (H-
Kb) bone marrow. To establish high-grade donor
himerism, allogeneic transplanted mice were given
LI (25  106 C57BL/6 splenocytes IV) on day 21
fter transplantation (alloBMT/F1/d21-DLI). On
ay 42 following BMT, EAE was induced and after
2 days, splenocyte proliferation assays against
OG35-55 were performed.
High-level donor chimerism was achieved in ani-
als receiving alloBMT/F1/d21-DLI (Figure 2a)
77%  3.8% for T cells and 96%  0.7% for B
ells on day 63 after BMT, n  36). EAE induction
n day 42 resulted in clinical EAE in 83% (n  12)
igure 2. Evolution of mean % donor T and B cell chimerism, mea
ssays against MOG35-55 in the C57BL/6 ¡ B6SJLF1 BMT mode
nd alloBMT/F1/d47-DLI, as determined by ﬂow cytometric analys
f EAE on day 42 after alloBMT/F1/d21-DLI, alloBMT/F1/d47-D
timuation index of splenocyte stimulation assays against MOG
lloBMT/F1/d47-DLI, synBMT/F1, and compared to host- and donor-tyf synBMT/F1 mice and in 67% (n  12) of al-
oBMT/F1/d21-DLI mice (NS compared to control
ost-type EAE mice (80%, n  15), Fisher’s exact).
linical EAE course and mean disease scores were
imilar in all 3 groups (Table 1 and Figure 2b)
mean EAE score  SEM of 1.4  0.2, 1.2  0.4,
.4  0.2 for synBMT/F1, alloBMT/F1/d21-DLI,
nd control host-type EAE, respectively, NS, Mann-
hitney U ). MOG35-55-speciﬁc proliferation assays
n day 54 after BMT showed similarly high prolifer-
tive responses in splenocytes from synBMT/F1, al-
oBMT/F1/d21-DLI, and host- and donor-type EAE
ontrol mice (Figure 2c) (mean SI  SEM of 5.3 
.4, 4.1  0.9, 3.4  0.9, and 3.8  1.1 for synBMT/
1, alloBMT/F1/d21-DLI, control host, and donor-
ype EAE mice, respectively, NS, Mann-Whitney U ).
Hence, high-level allogeneic chimerism in radia-
ion chimeras of EAE-susceptible host and donor
trains did not result in protection from EAE.
disease score, and mean stimulation index of splenocyte stimulation
ean % donor T and B cell chimerism after alloBMT/F1/d21-DLI
ripheral blood samples. b, Mean EAE disease score after induction
MT/F1, and compared to host-type EAE control animals. c, Mean
fter induction of EAE on day 42 after alloBMT/F1/d21-DLI,n EAE
l. a, M
is of pe
LI, synB
35-55 a
pe EAE control animals.
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GVA Effect in EAE 633igh-Grade Alloreactivity between
AE-Susceptible Strains Provides
rotection from EAE
To evaluate the extent to which alloreactivity can
ontribute to the protective effect of allogeneic BMT
or EAE, EAE-susceptible strains of mice were used in
different experimental setups.
First, in the alloBMT/F1 host-type mice, trans-
lanted and induced for EAE as described above, the
evel of alloreactivity, at the time of EAE develop-
ent, was augmented by giving DLI (50 106 donor-
ype splenocytes IV) 7 days after EAE induction
alloBMT/F1/d47-DLI). The EAE disease course as
ell as the ex vivo proliferative response to MOG35-55
ere evaluated.
On day 63 after allogeneic BMT, donor chimer-
sm was evaluated and showed high-grade donor chi-
erism (58%  3.3% donor-T cell-chimerism and
7%  3.8% donor-B cell-chimerism, n  39), as was
chieved in alloBMT/F1/d21-DLI mice (Figure 2a).
n alloBMT/F1/d47-DLI chimeras, the EAE inci-
ence was 54% (n  13), which was comparable to
hat of alloBMT/F1/d21-DLI chimera (67%, n  12)
nd control host-type EAE mice (80%; n  15) (NS,
ann-Whitney U ). However, the mean disease score
nd EAE course were signiﬁcantly lower in alloBMT/
1/d47-DLI animals than in control host-type EAE
ice (Table 1 and Figure 2b) (mean EAE score 
EM of 0.7 0.2 and 1.4 0.2 for alloBMT/F1/d47-
LI and control host-type EAE, respectively, P .05,
ann-Whitney U ). MOG35-55 speciﬁc proliferation
esponses were similar in alloBMT/F1/d47-DLI mice
nd controls (Figure 2c) (mean SI  SEM of 5.3 
.9, 3.4  0.9, and 3.8  1.1 for alloBMT/F1/d47-
LI, control host, and donor-type EAE, respectively,
S, Mann-Whitney U ).
Because DLI in alloBMT/F1/d47-DLI radiation
himeras resulted in the attenuation of EAE disease
ourse, in a next step, the same EAE-susceptible
trains were used in a related model in which higher
evels of alloreactivity were induced by repeated DLI.
t is well known that F1 hybrids can reject parental
ymphocytes on the basis of hybrid resistance [31].
owever, in some strain combinations, hybrid resis-
ance can be overcome and results in high-grade pa-
ental anti-F1 alloreactivity [32].
For 4 consecutive weeks, unconditioned B6SJLF1
ost-type mice were given weekly DLI (50  106
57BL/6 donor-type splenocytes IV) (DLI/F1). On
ay 42 after the ﬁrst DLI, EAE was induced in
LI/F1 chimeras and control host-type mice. On day
4, MOG35-55-speciﬁc splenocyte proliferation assays
ere performed.
Mixed chimerism was obtained in 60% of DLI/F1
nimals (69% 5.0% for T cells and 71% 6.9% for
cells on day 63 after the ﬁrst DLI, n 53) (Figure 3a), mhereas 40% of animals rejected the DLI grafts (n 
5). Following EAE induction, complete prevention
f EAE symptoms was seen in the mixed chimeras
n  17) (Table 1 and Figure 3b). Importantly, these
LI/F1 chimeras showed a complete loss of the pro-
iferative response against MOG35-55 (Figure 3c)
mean SI  SEM of 1.0  0.1, 3.4  0.9, and 3.8 
.1 for DLI/F1, control host, and donor-type EAE,
espectively, P  .05, Mann-Whitney U ).
Finally, to document the difference in level of
lloreactivity in these 2 models, MLR were per-
ormed. At the end of each experiment (d 60), lympho-
ytes derived from alloBMT/F1/d47-DLI and DLI/F1
himeras were stimulated in vitro with host-type lym-
hocytes. Whereas alloBMT/F1/d47-DLI chimeras
ailed to generate a strong in vitro antihost response,
LI/F1 chimeras showed a high level of alloreactivity
Figure 4).
Collectively, these data show that in a genetically
AE-susceptible background, robust protection from
AE can be obtained in the context of high-level
lloreactivity, obtained by DLI.
ISCUSSION
The immunologic mechanisms involved in the po-
ential therapeutic effect of syngeneic and allogeneic
MT for MS were studied by investigating the inﬂu-
nce of different protocols of murine BMT and DLI
n the EAE susceptibility of recipient mice.
In the ﬁrst weeks after TBI and BMT, a transient
eriod of protection from EAE was observed in syn-
eneic as well as allogeneic chimeras, which may be
ttributed to myeloablation and subsequent immu-
oincompetence. Previous rodent studies addressing
he effect of therapeutic syngeneic BMT on EAE have
llustrated the importance of removing the encephali-
ogenic T cells. The use of a nonmyeloablative regi-
en or syngeneic transplantation with bone marrow
ells derived from EAE-diseased donors (pseudoau-
ologous BMT) were shown to be less efﬁcient in
reventing EAE relapses than myeloablative regimens
r syngeneic BMT from a healthy donor [21-23]. In
ontrast to these therapeutic BMT models, in our
odel BMT was performed in naive EAE-susceptible
ice. Protection therefore probably results from lym-
hopenia and immunoincompetence in the early post-
ransplant period rather than from elimination of my-
lin-reactive T cells and “resetting” of these cells.
his is further exempliﬁed by the observation that,
uring the period in which transplanted mice were
linically protected, direct stimulation of their lym-
hocytes with MOG35-55 ex vivo, did produce a good
roliferative response.
In addition to the effects of postconditioning im-
unoincompetence, it is thought that, in MS patients,
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B. Van Wijmeersch et al.634hanges in the T cell repertoire, induced by myeloa-
lation and bone marrow reconstitution, contribute to
revention of further disease relapse [33,34]. In our
tudy, syngeneically transplanted mice and allogeneic
ow-grade chimeras exhibited—no more than 6 weeks
fter BMT—reappearance of EAE susceptibility, with
nchanged incidence and disease course. This argues
gainst the hypothesis that post BMT immune recon-
titution alters the autoimmune repertoire [35].
Two recent studies have evaluated the reconstitu-
ion of the T cell repertoire in MS patients following
utologous BMT [33,34]. It was found that, in the ﬁrst
ear, the extrathymic pathway of T cell reconstitution
redominates, during which lymphopenia-associated
omeostatic proliferation is thought to cause myelin-
eactive T cells to undergo activation induced cell
eath [35-39]. However, others have shown that the
ame mechanism potentiates autoreactive CD4 T
igure 3. Evolution of mean % donor T and B cell chimerism, mea
ssays against MOG35-55 in the C57BL/6¡B6SJLF1 DLI model. a
ow cytometric analysis of peripheral blood samples. b, Mean EAE
nd compared to host-type EAE control animals. c, Mean stimuatio
f EAE on day 42 after DLI/F1 and compared to host- and donorells in experimental autoimmune arthritis, and that Inhibition of this process is able to prevent disease
40]. In the second year, repopulation by new thymic
migrants is thought to result in a diversiﬁcation and
enewal of the T cell repertoire (TCR) [41,42]. How-
ver, the long-term clinical relevance of this diversi-
ed and broadened TCR is not known. In experimen-
al models of EAE, this immune reeducation after
yeloablation has not yet been studied.
Our data indicate that syngeneic BMT carries a
igh risk of recurrence and that any beneﬁcial effect
robably results from immunoincompetence as a re-
ult of myeloablation, which may lead to unacceptable
ide effects in MS patients.
The observation that, early after BMT, syngeneic
nd low-grade allogeneic chimeras—although clini-
ally protected—showed preserved MOG35-55-spe-
iﬁc proliferative responses ex vivo, supports the sub-
equent evolution toward clinical EAE development.
disease score, and mean stimulation index of splenocyte stimulation
% donor T and B cell chimerism after DLI/F1, as determined by
f diseased animals after induction of EAE on day 42 after DLI/F1
of splenocyte stimulation assays against MOG35-55 after induction
AE control animals.n EAE
, Mean
score o
n indexn contrast, high-grade allogeneic chimeras were,
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GVA Effect in EAE 635arly as well as later after transplantation, protected
rom clinical EAE and resistant to ex vivo stimulation
ith MOG35-55, indicating that a sufﬁcient level of
onor chimerism from an EAE-resistant donor is re-
uired to change the susceptibility to EAE.
In humans, the role of genetic susceptibility for
S is well established. A genetic susceptibility locus is
nown to reside within the HLA locus on chromo-
ome 6, with myelin-reactive T cells developing as a
esult from their binding to self (myelin)-peptides
resented in the context of the “autoimmune-prone”
r “unstable” HLA antigen [43,44]. It is hypothesized
hat allogeneic BMT provides the recipient’s immune
ystem with “stable” or “protective” HLA antigens
nd that formation of crossreactive allogeneic-HLA-
eptide complexes on donor-derived APCs results in
peciﬁc thymic deletion of the host-type myelin-reac-
ive T cells [45]. However, in experimental models of
ajor MHC-mismatched BMT, the mechanisms by
hich donor hematopoietic cells induce elimination
r tolerance of newly developing autoimmune-prone
ost T cells remains incompletely understood [46].
ecause in our study only high-level, and not low-
evel allogeneic chimerism, was able to confer protec-
ion from EAE, and because low-level thymic chimer-
sm theoretically would be sufﬁcient to induce clonal
eletion of autoreactive T cells, this mechanism of
ction does not sufﬁciently explain the observed pro-
ective effect on EAE susceptibility.
When high-level allogeneic chimerism from an
AE-susceptible donor was induced, protection from
AE development or loss of ex vivo MOG35-55-spe-
iﬁc proliferative response were not seen, further
orroborating the importance of a change in genetic
usceptibility. However, an alternative explanation
or this observation might be the difference in al-
igure 4. Mean stimulation index of mixed lymphocyte reactions
MLR) of splenocytes derived from DLI/F1 and alloBMT/F1/d47-
LI animals at 60 days after transplantation. One of 2 representa-
ive experiments is depicted.oreactivity between the Balb/c¡C57BL/6 fully vHC-disparate transplantation model, and the MHC
aplotype-mismatched C57BL/6¡B6SJLF1 trans-
lantation model. Hypothesizing that alloreactivity
lays a role in lowering susceptibility to EAE, without
owering the genetic susceptibility to EAE, we at-
empted to raise the level of alloreactivity in the haploi
entical BMT model. We were able to show that a
oderate increase of alloreactivity at the time of EAE
evelopment by means of DLI resulted in a partial
linical protection from EAE. A further increase of the
evel of alloreactivity, in a model of repetitive DLI
ithout previous conditioning, provided complete
linical protection, as well as complete loss of ex vivo
OG35-55-speciﬁc proliferative responses. The clear
ssociation of protection from EAE and high-grade
lloreactivity, as documented by the development of
ixed chimerism and ex vivo MLR reactivity, with
esistance to EAE and MOG35-55-speciﬁc proliferation,
trongly suggests that alloreactive T cells eliminate
otentially encephalitogenic T cells, and the existence
f an alloreactivity-based GVA-effect.
It has been shown that EAE induction of mice
ith MOG35-55 results in the production of MOG35-55-
peciﬁc antibodies. However, Marta et al. [47] have
hown that only MOG35-55-speciﬁc antibodies in-
uced by human MOG35-55 and not those induced by
at- or mouse-type MOG35-55 are pathogenic, indicat-
ng that murine MOG35-55-induced EAE develops in
B cell-independent manner [47]. Preliminary data in
ur C57BL/6¡B6SJLF1 models failed to reveal an
ffect of alloreactivity on the levels of anti-MOG35-55
ntibodies. Therefore, this indicates that, even if non-
athogenic, effects on anti-MOG35-55 antibody-levels
re not involved in the alloreactivity-based protection
rom EAE.
Because this model depends on a strong graft-
ersus-host response [48], it carries an increased risk
f GVHD. However, none of the animals developed
linical signs of GVHD, which in this model includes
eight loss, hunched posture, rufﬂed fur, and diarrhea
data not shown). The mechanisms involved in pre-
enting GVHD and in keeping the GVH response
onﬁned to the lymphohematopoietic system are the
ubjects of further studies. These may include regula-
ory mechanisms, which may also play a role in mod-
lating EAE susceptibility by elimination, anergy in-
uction or suppression of myelin-reactive T cells
49,50]. In this respect, Herrmann et al. [27] recently
ocumented an increase in CD4CD25Foxp3 reg-
latory T cells in a rat model of EAE after syngeneic
s well as MHC-matched allogeneic BMT, and sug-
ested this to be involved in the restoration of myelin
olerance. The observation that in our DLI-induced
igh-grade chimeras the degree of EAE susceptibility
id not convert into that of donor-type mice but, in
act, was substantially lower, suggests the possible in-
olvement of regulatory mechanisms. However, pre-
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B. Van Wijmeersch et al.636iminary data indicate that the frequencies of
D4Foxp3 regulatory T cells are similar in DLI/
1, alloBMT/F1/d21-DLI and control host-type an-
mals.
In conclusion, our data suggest that immunoin-
ompetence, related to the BMT procedure, plays a
ole in the protection from EAE seen early after syn-
eneic and allogeneic BMT. We further show that a
hange in genetic EAE susceptibility after allogeneic
MT provides longer term protection from EAE, but
equires a sufﬁciently high level of donor chimerism.
inally, and most importantly, we provide evidence
or a GVA effect, associated with strong alloreactivity,
hich can robustly abrogate EAE susceptibility. Re-
ent evolutions in the treatment of hematologic ma-
ignancies with allogeneic HSCT include the use of
educed-toxicity, so-called nonmyeloablative trans-
lant regimens, which are often used in combination
ith DLI to augment donor chimerism and obtain
VL effect [18,51-53]. This approach, which relies on
osttransplant induction of alloreactivity, has opened
reatment opportunities for older and weaker patients
ith hematologic malignancies and may do so for
atients with MS. Our data therefore provide a basis
or the exploration of this type of allogeneic transplant
egimen in the treatment of MS and other AIDS.
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